Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Schrdinger, Inc., together with its subsidiaries, provides physics-based software platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on selling its software for drug discovery in the life sciences industry, as well as to customers in materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrdinger, Inc. was incorporated in 1990 and is based in New York, New York.

Schrdinger, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

NEW YORK--(BUSINESS WIRE)--SCHRDINGER, INC. (NASDAQ: SDGR) TODAY REPORTED THAT ON SEPTEMBER 14, 2025, THE COMPANY GRANTED RESTRICTED STOCK UNITS (RSUS) WITH RESPECT TO 1,666 SHARES OF THE COMPANY'S COMMON STOCK TO FOUR NEWLY HIRED EMPLOYEES. THESE GRANTS WERE MADE PURSUANT TO THE COMPANY'S 2021 INDUCEMENT EQUITY INCENTIVE PLAN, WERE APPROVED BY THE COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS PURSUANT TO A DELEGATION BY THE COMPANY'S BOARD OF DIRECTORS, AND WERE MADE AS A MATERIAL INDUCEME.

SCHRDINGER REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

NEW YORK--(BUSINESS WIRE)--SCHRDINGER, INC. (NASDAQ: SDGR) TODAY ANNOUNCED THAT MANAGEMENT WILL PARTICIPATE IN A FIRESIDE CHAT AT THE MORGAN STANLEY 23RD ANNUAL GLOBAL HEALTHCARE CONFERENCE. THE LIVE PRESENTATION WILL TAKE PLACE ON MONDAY, SEPTEMBER 8, 2025 AT 11:30 A.M. E.T. THE LIVE WEBCAST CAN BE ACCESSED IN THE INVESTORS SECTION OF SCHRDINGER'S WEBSITE AND WILL BE ARCHIVED FOR APPROXIMATELY 90 DAYS FOLLOWING THE EVENT. ABOUT SCHRDINGER SCHRDINGER IS TRANSFORMING MOLECULAR DISCOVERY WI.

SCHRDINGER TO PRESENT AT MORGAN STANLEY GLOBAL HEALTHCARE CONFERENCE

NEW YORK--(BUSINESS WIRE)--SCHRDINGER, INC. (NASDAQ: SDGR) TODAY REPORTED THAT ON AUGUST 15, 2025, THE COMPANY GRANTED RESTRICTED STOCK UNITS (RSUS) WITH RESPECT TO 1,875 SHARES OF THE COMPANY'S COMMON STOCK TO TWO NEWLY HIRED EMPLOYEES. THESE GRANTS WERE MADE PURSUANT TO THE COMPANY'S 2021 INDUCEMENT EQUITY INCENTIVE PLAN, WERE APPROVED BY THE COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS PURSUANT TO A DELEGATION BY THE COMPANY'S BOARD OF DIRECTORS, AND WERE MADE AS A MATERIAL INDUCEMENT T.

NEW YORK--(BUSINESS WIRE)--SCHRDINGER, INC. (NASDAQ: SDGR) TODAY ANNOUNCED THE DISCONTINUATION OF THE CLINICAL DEVELOPMENT PROGRAM FOR SGR-2921, ITS CDC7 INHIBITOR, WHICH WAS BEING EVALUATED IN A PHASE 1 DOSE-ESCALATION STUDY IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC SYNDROMES. DESPITE EARLY EVIDENCE OF MONOTHERAPY ACTIVITY OBSERVED IN THE PHASE 1 STUDY, BASED ON THE PROFILE OBSERVED TO DATE, INCLUDING TWO EMERGENT EVENTS WHERE SGR-2921 WAS CONSID.

SCHRDINGER ANNOUNCES DISCONTINUATION OF SGR-2921 PROGRAM

NEW YORK--(BUSINESS WIRE)--SCHRDINGER TODAY ANNOUNCED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2025.

SCHRDINGER REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS

NEW YORK--(BUSINESS WIRE)--SCHRDINGER (NASDAQ: SDGR) WILL REPORT ITS SECOND QUARTER 2025 FINANCIAL RESULTS ON WEDNESDAY, AUGUST 6, 2025, AFTER THE FINANCIAL MARKETS CLOSE. THE COMPANY WILL HOST A CONFERENCE CALL AND WEBCAST AT 4:30 P.M. ET. THE LIVE WEBCAST CAN BE ACCESSED IN THE INVESTORS SECTION OF SCHRDINGER'S WEBSITE AND WILL BE ARCHIVED FOR APPROXIMATELY 90 DAYS FOLLOWING THE EVENT. ABOUT SCHRDINGER SCHRDINGER IS TRANSFORMING MOLECULAR DISCOVERY WITH ITS COMPUTATIONAL PLATFORM, WHICH.

SCHRDINGER TO ANNOUNCE SECOND QUARTER 2025 FINANCIAL RESULTS ON AUGUST 6

THE MATERIAL INFORMATICS COMPANIES QUADRANT PRESENTS AN IN-DEPTH ANALYSIS OF THE GLOBAL MATERIAL INFORMATICS MARKET. THIS INDUSTRY REVIEW HIGHLIGHTS LEADING COMPANIES, TECHNOLOGICAL ADVANCEMENTS, AND TRENDS, EVALUATING OVER 140 COMPANIES TO IDENTIFY THE TOP 17 LEADERS. MATERIAL INFORMATICS LEVERAGES SOFTWARE TO ADVANCE MATERIALS SCIENCE, AIDING INDUSTRIES LIKE AUTOMOTIVE, AEROSPACE, AND ELECTRONICS. COMPANIES LIKE SCHRDINGER, DASSAULT SYSTMES, AND CITRINE INFORMATICS ARE KEY PLAYERS, EMPLOYING PARTNERSHIPS AND INNOVATIONS TO ENHANCE THEIR MARKET POSITION. THIS QUADRANT ASSESSES COMPANIES ON REVENUE, GROWTH STRATEGIES, AND PRODUCT FOOTPRINT, UNDERSCORING THE DYNAMIC NATURE OF THE MATERIAL INFORMATICS SECTOR. THE MATERIAL INFORMATICS COMPANIES QUADRANT PRESENTS AN IN-DEPTH ANALYSIS OF THE GLOBAL MATERIAL INFORMATICS MARKET. THIS INDUSTRY REVIEW HIGHLIGHTS LEADING COMPANIES, TECHNOLOGICAL ADVANCEMENTS, AND TRENDS, EVALUATING OVER 140 COMPANIES TO IDENTIFY THE TOP 17 LEADERS. MATERIAL INFORMATICS LEVERAGES SOFTWARE TO ADVANCE MATERIALS SCIENCE, AIDING INDUSTRIES LIKE AUTOMOTIVE, AEROSPACE, AND ELECTRONICS. COMPANIES LIKE SCHRDINGER, DASSAULT SYSTMES, AND CITRINE INFORMATICS ARE KEY PLAYERS, EMPLOYING PARTNERSHIPS AND INNOVATIONS TO ENHANCE THEIR MARKET POSITION. THIS QUADRANT ASSESSES COMPANIES ON REVENUE, GROWTH STRATEGIES, AND PRODUCT FOOTPRINT, UNDERSCORING THE DYNAMIC NATURE OF THE MATERIAL INFORMATICS SECTOR.

MATERIAL INFORMATICS COMPANY EVALUATION REPORT 2025 | SCHRODINGER, DASSAULT SYSTMES, AND CITRINE INFORMATICS DRIVE MARKET GROWTH THROUGH AI, SIMULATION, AND COLLABORATION

NEW YORK--(BUSINESS WIRE)--SCHRDINGER, INC. (NASDAQ: SDGR) TODAY REPORTED THAT ON JULY 14, 2025, THE COMPANY GRANTED RESTRICTED STOCK UNITS (RSUS) WITH RESPECT TO 3,488 SHARES OF THE COMPANY'S COMMON STOCK TO THREE NEWLY HIRED EMPLOYEES. THESE GRANTS WERE MADE PURSUANT TO THE COMPANY'S 2021 INDUCEMENT EQUITY INCENTIVE PLAN, WERE APPROVED BY THE COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS PURSUANT TO A DELEGATION BY THE COMPANY'S BOARD OF DIRECTORS, AND WERE MADE AS A MATERIAL INDUCEMENT T.

NEW YORK & CAMBRIDGE, MASS.--(BUSINESS WIRE)--AJAX THERAPEUTICS, INC. AND SCHRDINGER, INC. (NASDAQ: SDGR) TODAY ANNOUNCED AN EXPANSION OF THEIR EXCLUSIVE RESEARCH COLLABORATION TO INCLUDE A NEW JANUS KINASE (JAK) TARGET. THE PARTNERSHIP WAS ESTABLISHED IN 2019 WITH A GOAL OF LEVERAGING SCHRDINGER'S ADVANCED COMPUTATIONAL PLATFORM AND AJAX'S STRUCTURAL BIOLOGY INSIGHTS TO DEVELOP A PIPELINE OF NOVEL MOLECULES, WITH A FOCUS ON JAK INHIBITORS. AJAX'S LEAD CANDIDATE FROM THE COLLABORATION, AJ1-11.

AJAX THERAPEUTICS AND SCHRDINGER EXPAND RESEARCH COLLABORATION TO INCLUDE ADDITIONAL JAK TARGET

NEW YORK , JULY 2, 2025 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF SCHRDINGER, INC.("SCHRDINGER" OR THE "COMPANY") (NASDAQ: SDGR).SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON AT NEWACTION@POMLAW.COMOR 646-581-9980, EXT.

Schrdinger, Inc.

SDGR

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Schrdinger, Inc.

SDGR.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

SDGR